BiotechTube

atorvastatin + inclisiran

ApprovedActive
1 views this week 0 watching⚡ Active
Interest: 47/100
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Plaque, Atherosclerotic

Conditions

Plaque, Atherosclerotic

Trial Timeline

Jul 9, 2024 → Jun 24, 2026

NCT ID
NCT06372925

About atorvastatin + inclisiran

atorvastatin + inclisiran is a approved stage product being developed by Novartis for Plaque, Atherosclerotic. The current trial status is active. This product is registered under clinical trial identifier NCT06372925. Target conditions include Plaque, Atherosclerotic.

What happened to similar drugs?

20 of 20 similar drugs in Plaque, Atherosclerotic were approved

Approved (20) Terminated (6) Active (0)
✅alefacept + polyvalent pneumococcal vaccineAstellas PharmaApproved
✅alefaceptAstellas PharmaApproved
✅alefaceptAstellas PharmaApproved
✅AlefaceptAstellas PharmaApproved
✅Halobetasol Topical LotionSun PharmaceuticalApproved
✅Topicort® (desoximetasone) Topical Spray, 0.25%Sun PharmaceuticalApproved
✅KHK4827-Active + KHK4827-PlaceboKyowa KirinApproved

Hype Score Breakdown

Clinical
20
Activity
12
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06372925ApprovedActive

Competing Products

20 competing products in Plaque, Atherosclerotic

See all competitors
ProductCompanyStageHype Score
CT-P17 + EU-approved HumiraCelltrionPhase 3
40
CT-P55 + EU-approved CosentyxCelltrionPhase 3
44
alefacept + polyvalent pneumococcal vaccineAstellas PharmaApproved
43
alefaceptAstellas PharmaPhase 3
40
Amevive exposureAstellas PharmaPre-clinical
18
alefacept + placeboAstellas PharmaPhase 3
40
alefaceptAstellas PharmaApproved
43
alefaceptAstellas PharmaApproved
35
AlefaceptAstellas PharmaApproved
43
Halobetasol PropionateSun PharmaceuticalPhase 2
27
Placebo + SCD-044_Low Dose (Dose 1) + SCD-044_Intermediate Dose (Dose 2) + SCD-044_High Dose (Dose 3)Sun PharmaceuticalPhase 2
35
DSXS + PlaceboSun PharmaceuticalPhase 3
40
DSXSSun PharmaceuticalPhase 2
35
DSXS topicalSun PharmaceuticalPhase 2
35
Halobetasol Topical LotionSun PharmaceuticalApproved
35
Tildrakizumab 200 mg + Tildrakizumab 100 mg + Matching PlaceboSun PharmaceuticalPhase 3
40
DSXS1411 + PlaceboSun PharmaceuticalPhase 2
35
Tildrakizumab + PlaceboSun PharmaceuticalPhase 3
40
Tildrakizumab 200 mg + Tildrakizumab 100 mg + Tildrakizumab Placebo + Etanercept Placebo + Etanercept 50 mgSun PharmaceuticalPhase 3
40
MK-3222 200 mg + MK-3222 100 mg + Placebo to MK-3222 + Placebo to Etanercept + Etanercept 50 mgSun PharmaceuticalPhase 3
32